BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study

Abstract

In this study, 94% of patients showed partial response or better to TT. Adverse events were acceptable. Further research is needed to establish standardized protocols; however, these results advocate for a NEO approach in invasive PCPs.